Atrial natriuretic peptide

Sunda Energy signed an MoU with Timor-Leste government and state-owned companies to evaluate a development concept for Chuditch PSC gas resources, including pipeline export to Bayu Undan field and LNG facilities on Timor-Leste's south coast. The MoU outlines plans for accelerated development post Chuditch-2 appraisal well in 2025, with ongoing engineering and commercial studies evaluating feasibility. Commitments include SundaGas delivering gas via Bayu Undan facilities and MPMR expediting receiving and transmission facilities. These commitments are non-binding, pending successful appraisal and future binding documentation.

Dobutamine, an inotropic agent, chosen to address neurohormonal response in subclinical hemodynamic deterioration, administered at 5 μg/kg/min to mitigate tachyarrhythmia risk. Patients receive 24-h IV infusion of dobutamine or placebo, with potential dose reduction for persistent tachyarrhythmia. Primary endpoint is between-group difference in peak proBNP within 48 h. Secondary endpoints include hemodynamic function, pulse rate, blood pressure, and biomarkers. Trial powered to show 30% reduction in proBNP levels with 88 patients, with 100 patients enrolled to account for dropouts.

Studies highlight endothelial dysfunction in critical illness, sepsis, and trauma, with biomarkers indicating glycocalyx injury and potential therapeutic targets like angiopoietin-Tie2 pathways.